The Need for Standardization of Low Molecular Weight Heparin (LMWH)

• References

• 1 Aiach M, Michaud A, Balian JL, Lefebvre M, Woler M, Fourtillan J. A new molecular weight heparin derivative. In vitro and in vivo studies. Thromb Res 1983; 31: 611-621
• 2 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985; 39: 631-636
• 3 Barrowcliffe TW, Curtis AD, Tomlinson TP, Hubbard AR, Johnson EA, Thomas DP. Standardization of low molecular weight heparins. A collaborative study. Thromb Haemostas 1985; 54: 675-679
• 4 Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986; 73: 204-208
• 5 Kakkar VV, Murray WJ G. Efficacy and safety of low molecular weight heparin (CY 216) in preventing post operative venous thromboembolism: a cooperative study. Brit J Surg 1985; 72: 789-791
• 6 Kher A, Barbier P. Personal communication and unpublished results.
• 7 Teien AN, Lie M. Evaluation of amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 1977; 10: 399-410
• 8 Walenga JM, Bara L, Samama M, Fareed J. Amidolytic antifactor Xa assays in the laboratory evaluation of heparin and low molecular weight fraction. Semin Thrombos Haemost 1985; 11: 104
• 9 Yin ET, Wessler S, Butler YV. Plasma heparin: a unique, practical submicrogram sensitive assay. J Lab Clin med 1973; 81: 298